These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 30480413)

  • 1. Colocalization of USP1 and РН domain of Bcr­Abl oncoprotein in terms of cronic myeloid leukemia cell rearrangements.
    Antonenko SV; Gurianov DS; Тelegeev GD
    Tsitol Genet; 2016; 50(4):11-5. PubMed ID: 30480413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of Bcr-Abl level in K562 cells.
    Antonenko SV; Telegeev GD
    Exp Oncol; 2020 Jun; 42(2):109-114. PubMed ID: 32602291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.
    Dixon AS; Constance JE; Tanaka T; Rabbitts TH; Lim CS
    Pharm Res; 2012 Apr; 29(4):1098-109. PubMed ID: 22183511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.
    Gao M; Huang ZL; Tao K; Xiao Q; Wang X; Cao WX; Xu M; Hu J; Feng WL
    Oncotarget; 2017 Jan; 8(2):3304-3314. PubMed ID: 27926512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
    von Bubnoff N; Peschel C; Duyster J
    Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.
    Dixon AS; Miller GD; Bruno BJ; Constance JE; Woessner DW; Fidler TP; Robertson JC; Cheatham TE; Lim CS
    Mol Pharm; 2012 Jan; 9(1):187-95. PubMed ID: 22136227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
    Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
    Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
    Peng C; Li S
    Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
    Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
    Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA.
    Li MJ; McMahon R; Snyder DS; Yee JK; Rossi JJ
    Oligonucleotides; 2003; 13(5):401-9. PubMed ID: 15000831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
    Kelani R; Monem F
    Int J Lab Hematol; 2015 Oct; 37(5):723-8. PubMed ID: 26059167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
    Li Q; Huang Z; Gao M; Cao W; Xiao Q; Luo H; Feng W
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
    Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular biology of chronic myeloid leukaemia.
    Melo JV
    Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia.
    Barnes DJ; Melo JV
    Acta Haematol; 2002; 108(4):180-202. PubMed ID: 12432215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of transformation by the BCR-ABL oncogene.
    Sattler M; Griffin JD
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):4-10. PubMed ID: 12783368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.